Blueprint Medicines (BPMC) Stock Price, News & Analysis

+1.68 (+1.85%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
788,709 shs
Average Volume
576,520 shs
Market Capitalization
$5.65 billion
P/E Ratio
Dividend Yield
Price Target

Blueprint Medicines MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
7.4% Downside
$85.43 Price Target
Short Interest
7.14% of Shares Sold Short
Dividend Strength
News Sentiment
0.86mentions of Blueprint Medicines in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$10.36 M Sold Last Quarter
Proj. Earnings Growth
From ($5.42) to ($2.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.82 out of 5 stars

Medical Sector

818th out of 909 stocks

Pharmaceutical Preparations Industry

384th out of 424 stocks

BPMC stock logo

About Blueprint Medicines Stock (NASDAQ:BPMC)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

BPMC Stock Price History

BPMC Stock News Headlines

Elon Musk’s Controversial New Project: “Apollo”
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
Piper Sandler Keeps Their Hold Rating on Blueprint Medicines (BPMC)
Decoding 6 Analyst Evaluations For Blueprint Medicines
Elon Musk’s Controversial New Project: “Apollo”
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
BPMC Apr 2024 90.000 put
BPMC Apr 2024 45.000 put
BPMC Apr 2024 120.000 call
BPMC Dec 2024 115.000 call
BPMC Jun 2024 115.000 call
BPMC Mar 2024 100.000 put
Stifel Nicolaus Keeps Their Buy Rating on Blueprint Medicines (BPMC)
See More Headlines
Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
14 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$249.38 million
Book Value
$2.15 per share


Free Float
Market Cap
$5.65 billion

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

BPMC Stock Analysis - Frequently Asked Questions

Should I buy or sell Blueprint Medicines stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 3 sell ratings, 2 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BPMC shares.
View BPMC analyst ratings
or view top-rated stocks.

What is Blueprint Medicines' stock price target for 2024?

14 equities research analysts have issued 1-year price objectives for Blueprint Medicines' shares. Their BPMC share price targets range from $43.00 to $115.00. On average, they expect the company's share price to reach $85.43 in the next twelve months. This suggests that the stock has a possible downside of 7.4%.
View analysts price targets for BPMC
or view top-rated stocks among Wall Street analysts.

How have BPMC shares performed in 2024?

Blueprint Medicines' stock was trading at $92.24 at the start of the year. Since then, BPMC stock has increased by 0.1% and is now trading at $92.29.
View the best growth stocks for 2024 here

Are investors shorting Blueprint Medicines?

Blueprint Medicines saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 4,370,000 shares, a drop of 15.1% from the March 15th total of 5,150,000 shares. Based on an average daily volume of 786,700 shares, the days-to-cover ratio is currently 5.6 days.
View Blueprint Medicines' Short Interest

When is Blueprint Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BPMC earnings forecast

How can I listen to Blueprint Medicines' earnings call?

Blueprint Medicines will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) issued its quarterly earnings data on Thursday, February, 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating the consensus estimate of ($2.04) by $0.22. The biotechnology company earned $71.96 million during the quarter, compared to analyst estimates of $67.34 million. Blueprint Medicines had a negative net margin of 203.30% and a negative trailing twelve-month return on equity of 191.56%. The business's quarterly revenue was up 85.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($2.65) earnings per share.

What is Kate Haviland's approval rating as Blueprint Medicines' CEO?

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

Blueprint Medicines (BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Raymond James Financial Services Advisors Inc. (0.06%), Diversified Trust Co (0.02%), Handelsinvest Investeringsforvaltning (0.01%), Clarus Wealth Advisors (0.00%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Ariel Hurley, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Percy H Carter and Tracey L Mccain.
View institutional ownership trends

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BPMC) was last updated on 4/24/2024 by Staff

From Our Partners